Social Anxiety Disorder (SAD) Market Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc, Aurobindo Phar

DelveInsight's "Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Social Anxiety Disorder, historical and forecasted epidemiology as well as the Social Anxiety Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Social Anxiety Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Social Anxiety Disorder Market Forecast https://www.delveinsight.com/sample-request/social-anxiety-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Social Anxiety Disorder Market Report:
• The Social Anxiety Disorder market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The National Institute of Mental Health (NIMH) predicts that 12.1% of people, or around 1 in 8, may experience social anxiety disorder at some point in their lives. According to the U.S. National Institutes of Health (NIH), SAD is the third most prevalent psychiatric disorder after depression and substance abuse. According to estimates, considerable impairment affected 29.9% of people with social anxiety disorder in the past year.
• The Anxiety and Depression Association of America (ADAA) 2021 estimates that 15.3 million people, or 6.8% of the US population, have social anxiety disorder. Many patients frequently obtained inaccurate diagnoses as a result of the disease.
• In the UK population, social anxiety disorder affects 12% of people over the course of their lifetimes, according to the National Institute of Health and Care Excellence (NICE)
• Key Social Anxiety Disorder Companies: GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc, Aurobindo Pharma Ltd, Korea Pharma Co Ltd, Syneos Health Inc, Vistagen Therapeutics, Bionomics, EmpowerPharm Inc., Bionomics Limited, Pherin Pharmaceuticals, H. Lundbeck A/S, Pfizer, Avera Pharmaceuticals, Biohaven Pharmaceuticals, Cephalon, Pherin Pharma, Eli Lilly and Company, Bristol-Myers Squibb, UCB Pharma, and others
• Key Social Anxiety Disorder Therapies: PH94B, BNC210, 225 mg BNC210, PH94B, Escitalopram, quetiapine, Venlafaxine ER, paroxetine, AV608, BHV-0223, Gabitril, PH94B, Atomoxetine hydrochloride, Nefazodone, levetiracetam, and others
• The Social Anxiety Disorder epidemiology based on gender analyzed that females are more frequently diagnosed with SAD compared to males
• The Social Anxiety Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Social Anxiety Disorder pipeline products will significantly revolutionize the Social Anxiety Disorder market dynamics.

Social Anxiety Disorder Overview
Social anxiety disorder, commonly known as social phobia or SAD, is the most common mental health condition and is characterized by a significant, ongoing fear of being observed and judged by others in social situations.

Get a Free sample for the Social Anxiety Disorder Market Report
https://www.delveinsight.com/report-store/social-anxiety-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Social Anxiety Disorder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Social Anxiety Disorder Epidemiology Segmentation:
The Social Anxiety Disorder market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Social Anxiety Disorder
• Prevalent Cases of Social Anxiety Disorder by severity
• Gender-specific Prevalence of Social Anxiety Disorder
• Diagnosed Cases of Episodic and Chronic Social Anxiety Disorder

Download the report to understand which factors are driving Social Anxiety Disorder epidemiology trends @ Social Anxiety Disorder Epidemiology Forecast
https://www.delveinsight.com/sample-request/social-anxiety-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Social Anxiety Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Social Anxiety Disorder market or expected to get launched during the study period. The analysis covers Social Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Social Anxiety Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Social Anxiety Disorder Therapies and Key Companies
• PH94B: Vistagen Therapeutics, Bionomics
• BNC210: EmpowerPharm Inc.
• 225 mg BNC210: Pherin Pharmaceuticals
• PH94B: AstraZeneca
• Escitalopram: H. Lundbeck A/S
• quetiapine: Pfizer
• Venlafaxine ER: GlaxoSmithKline
• paroxetine: Avera Pharmaceuticals
• AV608: Biohaven Pharmaceuticals
• BHV-0223: Cephalon
• Gabitril: Pherin Pharma
• PH94B: Eli Lilly and Company
• Atomoxetine hydrochloride:
• Nefazodone: Bristol-Myers Squibb
• levetiracetam: UCB Pharma

Discover more about therapies set to grab major Social Anxiety Disorder market share @ Social Anxiety Disorder Treatment Market
https://www.delveinsight.com/sample-request/social-anxiety-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Social Anxiety Disorder Market Drivers
• Less competitive scenarios
• Fast-acting innovative emerging therapies
• Increasing awareness and Prevalence

Social Anxiety Disorder Market Barriers
• Lack of robust pipeline
• Barriers to treatment
• Psychological and financial burden

Scope of the Social Anxiety Disorder Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Social Anxiety Disorder Companies: GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc, Aurobindo Pharma Ltd, Korea Pharma Co Ltd, Syneos Health Inc, Vistagen Therapeutics, Bionomics, EmpowerPharm Inc., Bionomics Limited, Pherin Pharmaceuticals, H. Lundbeck A/S, Pfizer, Avera Pharmaceuticals, Biohaven Pharmaceuticals, Cephalon, Pherin Pharma, Eli Lilly and Company, Bristol-Myers Squibb, UCB Pharma, and others
• Key Social Anxiety Disorder Therapies: PH94B, BNC210, 225 mg BNC210, PH94B, Escitalopram, quetiapine, Venlafaxine ER, paroxetine, AV608, BHV-0223, Gabitril, PH94B, Atomoxetine hydrochloride, Nefazodone, levetiracetam, and others
• Social Anxiety Disorder Therapeutic Assessment: Social Anxiety Disorder current marketed and Social Anxiety Disorder emerging therapies
• Social Anxiety Disorder Market Dynamics: Social Anxiety Disorder market drivers and Social Anxiety Disorder market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Social Anxiety Disorder Unmet Needs, KOL's views, Analyst's views, Social Anxiety Disorder Market Access and Reimbursement

To know more about Social Anxiety Disorder companies working in the treatment market, visit @ Social Anxiety Disorder Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/social-anxiety-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Social Anxiety Disorder Market Report Introduction
2. Executive Summary for Social Anxiety Disorder
3. SWOT analysis of Social Anxiety Disorder
4. Social Anxiety Disorder Patient Share (%) Overview at a Glance
5. Social Anxiety Disorder Market Overview at a Glance
6. Social Anxiety Disorder Disease Background and Overview
7. Social Anxiety Disorder Epidemiology and Patient Population
8. Country-Specific Patient Population of Social Anxiety Disorder
9. Social Anxiety Disorder Current Treatment and Medical Practices
10. Social Anxiety Disorder Unmet Needs
11. Social Anxiety Disorder Emerging Therapies
12. Social Anxiety Disorder Market Outlook
13. Country-Wise Social Anxiety Disorder Market Analysis (2019-2032)
14. Social Anxiety Disorder Market Access and Reimbursement of Therapies
15. Social Anxiety Disorder Market Drivers
16. Social Anxiety Disorder Market Barriers
17. Social Anxiety Disorder Appendix
18. Social Anxiety Disorder Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Social Anxiety Disorder Epidemiology https://www.delveinsight.com/report-store/social-anxiety-disorder-sad-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Social Anxiety Disorder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Social Anxiety Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.